Key result
Pemafibrate XR is linked to ~35% lower triglycerides at 12 months in hypertriglyceridemia.
Why the study?
Real-world evidence regarding the long-term effectiveness and safety of pemafibrate extended-release, especially after switching from conventional twice-daily pemafibrate, is limited.
Does pemafibrate extended-release improve lipid profiles and liver-related biochemical parameters in patients with hypertriglyceridemia?
Observational (n=115)
No
Does pemafibrate extended-release improve lipid profiles and liver-related biochemical parameters in patients with hypertriglyceridemia?
Pemafibrate extended-release significantly reduced triglyceride levels and improved liver-related biochemical parameters over 12 months in real-world clinical practice, including in patients switched from the twice-daily formulation.
Answers are grounded in this paper and cite their sources.
May support once-daily pemafibrate XR in real-world hypertriglyceridemia; leaves open outcome benefits versus twice-daily formulation.
OBJECTIVE: Pemafibrate extended-release (XR), a once-daily formulation of pemafibrate, was developed to improve treatment convenience. However, real-world evidence regarding its long-term effectiveness, particularly after switching from conventional twice-daily pemafibrate, is limited. This study evaluated the efficacy and safety of pemafibrate XR in patients with hypertriglyceridemia. PATIENTS OR MATERIALS: This retrospective observational study included 115 patients treated with pemafibrate XR for 12 months. Changes in the lipid profiles, liver-related biochemical parameters, and metabolic parameters were evaluated. A subgroup analysis was performed in patients who switched from conventional twice-daily pemafibrate to pemafibrate XR. RESULTS: The triglyceride levels significantly decreased from 226 [142.5-368] mg/dL at baseline to 148 [112-203.5] mg/dL at 12 months (p<0.001). The high-density lipoprotein cholesterol levels significantly increased, whereas the low-density lipoprotein cholesterol levels remained unchanged. Liver-related parameters, including alanine aminotransferase, γ-glutamyl transpeptidase, and alkaline phosphatase, significantly improved, whereas the Fibrosis-4 index did not. The serum albumin levels increased, whereas the uric acid levels decreased after treatment. In the switch subgroup (n=75), the triglyceride and alanine aminotransferase levels significantly improved after the switch. CONCLUSION: Pemafibrate XR was associated with improvements in the triglyceride levels and liver-related biochemical parameters in real-world clinical practice. Among patients switched from twice-daily pemafibrate, favorable lipid and liver-related biochemical parameters were maintained during treatment with pemafibrate XR.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2026) conducted an observational in Hypertriglyceridemia (n=115). Pemafibrate extended-release vs. Baseline was evaluated on Triglyceride levels at 12 months (p=<0.001). Pemafibrate extended-release decreased median triglyceride levels from /dL at baseline to /dL at 12 months in patients with hypertriglyceridemia.
Synapse has enriched 10 related papers. Consider them for comparative context: